Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
- 1 August 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 6 (8), 1308-1315
- https://doi.org/10.1158/1541-7786.mcr-07-2159
Abstract
Most metastatic melanoma patients fail to respond to available therapy, underscoring the need for novel approaches to identify new effective treatments. In this study, we screened 2,000 compounds from the Spectrum Library at a concentration of 1 μmol/L using two chemoresistant melanoma cell lines (M-14 and SK-Mel-19) and a spontaneously immortalized, nontumorigenic melanocyte cell line (melan-a). We identified 10 compounds that inhibited the growth of the melanoma cells yet were largely nontoxic to melanocytes. Strikingly, 4 of the 10 compounds (mebendazole, albendazole, fenbendazole, and oxybendazole) are benzimidazoles, a class of structurally related, tubulin-disrupting drugs. Mebendazole was prioritized to further characterize its mechanism of melanoma growth inhibition based on its favorable pharmacokinetic profile. Our data reveal that mebendazole inhibits melanoma growth with an average IC50 of 0.32 μmol/L and preferentially induces apoptosis in melanoma cells compared with melanocytes. The intrinsic apoptotic response is mediated through phosphorylation of Bcl-2, which occurs rapidly after treatment with mebendazole in melanoma cells but not in melanocytes. Phosphorylation of Bcl-2 in melanoma cells prevents its interaction with proapoptotic Bax, thereby promoting apoptosis. We further show that mebendazole-resistant melanocytes can be sensitized through reduction of Bcl-2 protein levels, showing the essential role of Bcl-2 in the cellular response to mebendazole-mediated tubulin disruption. Our results suggest that this screening approach is useful for identifying agents that show promise in the treatment of even chemoresistant melanoma and identifies mebendazole as a potent, melanoma-specific cytotoxic agent. (Mol Cancer Res 2008;6(8):1308–15)Keywords
This publication has 32 references indexed in Scilit:
- Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanismCancer Chemotherapy and Pharmacology, 2008
- Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl‐2‐related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findingsJournal of Cutaneous Pathology, 2007
- Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic ImplicationsCancer Research, 2005
- Small Interfering RNA Targeting Bcl-2 Sensitizes Malignant MelanomaOligonucleotides, 2003
- Apoptosis and melanoma chemoresistanceOncogene, 2003
- The Effect ofO6-Alkylguanine-DNA Alkyltransferase and Mismatch Repair Activities on the Sensitivity of Human Melanoma Cells to Temozolomide, 1,3-bis(2-Chloroethyl)1-nitrosourea, and CisplatinJournal of Pharmacology and Experimental Therapeutics, 2003
- Bcl-2 Phosphorylation Required for Anti-apoptosis FunctionPublished by Elsevier BV ,1997
- P53 Mutation and c-fos Overexpression Are Associated With Detection of the Antigen VLA-2 in Human Melanoma Cell LinesPigment Cell Research, 1994
- Mode of action of benzimidazolesParasitology Today, 1990
- The mode of action of some benzimidazole drugs onTrichinella spiralisParasitology, 1987